Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

19,144 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Nrf2 as a target for cancer chemoprevention.
Yu X, Kensler T. Yu X, et al. Mutat Res. 2005 Dec 11;591(1-2):93-102. doi: 10.1016/j.mrfmmm.2005.04.017. Epub 2005 Jul 28. Mutat Res. 2005. PMID: 16054659 Review.
Nrf2-mediated induction of cytoprotective enzymes by 15-deoxy-Delta12,14-prostaglandin J2 is attenuated by alkenal/one oxidoreductase.
Yu X, Egner PA, Wakabayashi J, Wakabayashi N, Yamamoto M, Kensler TW. Yu X, et al. J Biol Chem. 2006 Sep 8;281(36):26245-52. doi: 10.1074/jbc.M604620200. Epub 2006 Jul 20. J Biol Chem. 2006. PMID: 16857669
NADPH alkenal/one oxidoreductase activity determines sensitivity of cancer cells to the chemotherapeutic alkylating agent irofulven.
Dick RA, Yu X, Kensler TW. Dick RA, et al. Clin Cancer Res. 2004 Feb 15;10(4):1492-9. doi: 10.1158/1078-0432.ccr-03-0162. Clin Cancer Res. 2004. PMID: 14977853
Illudins S and M were found to be rapidly metabolized by NADPH-dependent alkenal/one oxidoreductase (AOR) with maximal rates of 115.9 and 44.1 micromol x min(-1) mg(-1), and K(m)s of 308 and 109 microM, respectively. ...
Illudins S and M were found to be rapidly metabolized by NADPH-dependent alkenal/one oxidoreductase (AOR) with maximal rates of 115.9 and 44 …
Up-regulation of human prostaglandin reductase 1 improves the efficacy of hydroxymethylacylfulvene, an antitumor chemotherapeutic agent.
Yu X, Erzinger MM, Pietsch KE, Cervoni-Curet FN, Whang J, Niederhuber J, Sturla SJ. Yu X, et al. J Pharmacol Exp Ther. 2012 Nov;343(2):426-33. doi: 10.1124/jpet.112.195768. Epub 2012 Aug 15. J Pharmacol Exp Ther. 2012. PMID: 22895897 Free PMC article.
Identification of aflatoxin M1-N7-guanine in liver and urine of tree shrews and rats following administration of aflatoxin B1.
Egner PA, Yu X, Johnson JK, Nathasingh CK, Groopman JD, Kensler TW, Roebuck BD. Egner PA, et al. Chem Res Toxicol. 2003 Sep;16(9):1174-80. doi: 10.1021/tx034106u. Chem Res Toxicol. 2003. PMID: 12971806
Ti2P monolayer as a high performance 2-D electrode material for ion batteries.
Cheng Z, Zhang X, Zhang H, Liu H, Yu X, Dai X, Liu G, Chen G. Cheng Z, et al. Among authors: yu x. Phys Chem Chem Phys. 2020 Aug 11. doi: 10.1039/d0cp02874f. Online ahead of print. Phys Chem Chem Phys. 2020. PMID: 32778861
A Case of Resistance to Selective RET-TKI Therapy With Pleural-Genotyped MET Amplification and Response to Crizotinib.
Chen K, Zhang F, Pan G, Sheng J, Ye J, Xu Y, Yu X, Huang Z, Fan Y. Chen K, et al. Among authors: yu x. Clin Lung Cancer. 2020 Jul 20:S1525-7304(20)30229-1. doi: 10.1016/j.cllc.2020.07.007. Online ahead of print. Clin Lung Cancer. 2020. PMID: 32778510 No abstract available.
Ferroptosis, necroptosis, and pyroptosis in anticancer immunity.
Tang R, Xu J, Zhang B, Liu J, Liang C, Hua J, Meng Q, Yu X, Shi S. Tang R, et al. Among authors: yu x. J Hematol Oncol. 2020 Aug 10;13(1):110. doi: 10.1186/s13045-020-00946-7. J Hematol Oncol. 2020. PMID: 32778143 Review.
19,144 results
Jump to page